**Supplementary materials**

**Table 1**. PEV modifiers in *Drosophila*, human and mice, and associated pathways and human diseases.

*\** from[1] with additions accordingly <http://flybase.org/> and <https://www.uniprot.org/>

*\*\** from[2]

“–” - no data

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | ***Drosophila* (gene)** | **Mouse (protein)** | **Human (protein)** | **Function\*** | **Diseases \*\*** | **Pathways \*\*** | **References** |
| **Histone variants** | *H1* | H1.0 | H1.0 | Linker histone | – | – | [3] |
| *His2Av* | H2a/Za | H2A.Z | Heterochromatin-specific Н2a variant | – | – | [4] |
| **Histone modifiers** | *Su(var)3-1* (*JIL1*) | RPS6KA5 | RPS6KA5 | H3S10 serine/threonine phosphatase | – | – | [5, 6] |
| *Su*(*var*)*3*-*9* | SUV39H 1 (KMT1A)SUV39H 2 (KMT1B) | SUV39H1 (KMT1A) | H3K9 histone methyltransferase, binds НР1 | Facioscapulohumeral muscular dystrophy (FSHD).Retinoblastoma, lung adenocarcinoma, breast cancer. | Steroid hormones/nuclear receptors; TGF-β/BMP/Smad; Hedgehog; TNF-α/NF-κB. | [7] |
| *Su(var)4-20* | SUV420H 1 (KMT5B)SUV420H 2 (KMT5C) | SUV420H1(KMT5B) SUV420H2 (KMT5C) | H4K20 histone methyltransferase | – | – | [8-10] |
| *eggless* | SETDB1 | SETDB1 | H3K9 histone methyltransferase | – | – | [11, 12] |
| *HDAC3*, *HDAC4*, *HDAC6* | HDAC2b | HDAC2 | Histone deacetylase | Chronic obstructive pulmonary disease (COPD), asthma. Prostate, breast, kidney, gastric, colorectal, ovarian, endometrial cancer. | Steroid hormones/nuclear receptors; WNT/β-catenin; Hedgehog. | [13] |
| *Su(var)3-64B* (*HDAC1*, *RPD3*) | HDAC1 | HDAC1 | H3K9 deacetylase | Schizophrenia. Prostate, breast, kidney, gastric, colorectal, ovarian, endometrial cancer. | Steroid hormones/nuclear receptors; TGF-β/BMP/Smad; Hedgehog; TNF-α/NF-κB. | [14, 15] |
| *Su(var)3-3* | KDM1A | KDM1A | H3K4me3 demethylase | – | – | [16, 17] |
| *Su(var)3-6* | PPP1CC | PPP1CC | PP1, serine/threonine phosphatase | – | – | [18] |
| *Ial* (*aurora B*) | PPP1CC  | PPP1CC | H3S28 phosphatase  | – | – | [19] |
| *Chm* (*chameau*) | KAT7 | KAT7 | Myst-domain histone deacetylase, Su(var), enhancer of Polycomb repression | – | – | [20] |
| *Sce* | RNF2c | RING2 | H2A Lys118 ubiquitin ligase  |  |  | [21] |
| **Chromatin proteins** | *Su(var)2-5* (*HP1*) | HP1α, HP1β | HP1A,HP1B | Binds 2- and 3-methylated H3K9 and Su(var)3-9 | – | – | [22, 23] |
| *Su*(*var*)*2*-*HP2* | – | – | Binds HР1, enriched in heterochromatin | – | – | [24] |
| *Dom* (*Domina*) | – | – | Enriched in heterochromatin | – | – | [25] |
| *Pc* | CBX8 | CBX8 | Polycomb-complex component | – | – | [21, 26] |
| *Psc* | BMI1 | BMI1 | Polycomb-complex component | – | – | [21, 27] |
| *ph-d*, *ph-p* | PHC2, PHC3 | PHC2, PHC3 | Polycomb-complex component | – | – | [21] |
| *DLP* | DAXX | DAXX | – | – | – | [28] |
| *Ssrp*  | SSRP1 | SSRP1 | – | – | – | [28] |
| – | TRIM28 (TIF1B, MommeD9) | TRIM28 (TIF1B) | KRAB-ZFPs corepressor | Breast cancer. | Steroid hormones/nuclear receptors; G protein–coupled receptors andreceptor tyrosine kinases(ERK/MAPK, PI3K/AKT,JAK/STAT, JNK, PKC). | [29-31] |
| **Chromatin remodeling** | *dAtrx* (*XNP*) | ATRX | ATRX | – | ATRX syndrome, α-thalassemia myelodysplasiasyndrome.Acute myeloid leukemia. | – | [32] |
| *Acf1* | BAZ1Ba (ACF1, WSTF180) BAZ1B (WSTF, MommeD10) | BAZ1B (WSTF) | – | Williams-Beuren syndrome. | Steroid hormones/nuclear receptors. | [33, 34] |
| *Actr13E* | ARP6 | ACTR6 | – | – | – | [35] |
| *Mod(mdg4)*/ *E(var)3-93D* | – | – | Transcriptional regulator, has more than 20 trans-splicing isoforms | – | – | [36] |
| *Su(var)2-10* | PIAS1 | PIAS1 | PIAS protein, JAK/STAT pathway down-regulator , E3 SUMO-ligase | – | Steroid hormones/nuclear receptors; TGF-β/BMP/Smad; Hedgehog; TNF-α/NF-κB. | [37-39] |
| *E(var)3-64E*/ *Ubp64Evar1* | – | – | Ubiquitin-specific protease | – | – | [40] |
| *Su(z)5* | – | – | S- adenosylmethionine synthetase | – | – | [41] |
| – | LSH (Hells)  | – | Lymphocyte-specific helicase | – | – | [42] |
| **DNA-binding** | *D1* | HMGA1, HMGA2 | HMGA1, HMGA2 | Multi-AT-hook domain protein, minor groove binding, promotes gene repression, interacts with topoisomerase II | Diabetes, Silver-Russell syndrome. Breast, prostate, lung, pancreas, thyroid, ovarian, pituitary, gastric cancer and lipomas. | – | [33, 43, 44] |
| *mod* (*modulo*) | – | – | DNA- and RNA-binding, the phosphorylated form binds to rRNA | – | – | [45] |
| *pho* | YY1 | TYY1 | Binds 5'-CCGCCATNTT-3' and SBE -element, contribute to DNA reparation | Mental retardation syndrome. | TNF-α/NF-κB. | [46, 47] |
| *Su(var)3-7* | – |  | Zinc fingers protein binds HP1a and SU(VAR)3-9 | – | – | [48] |
| *salm*, *salr* | SALL1, -3, -4 | SALL1SALL4 |  | Townes-Brocks syndrome (TBS)Duane-radial ray syndrome (Okihiro Syndrome).Acute myeloid leukemia. | Hedgehog. | [49, 50] |
| *sens*, *sens-2* | GFILb |  |  | – | – | [51] |
| *Trl* (*trithorax-like*) (*E(var)*) | – | – | GAGA- transcription factor, binds DNA repeats | – | – | [52] |
| – | IKAROS | IKAROS | Binds gamma-satellite DNA | – | Notch/Delta. | [51] |
| – | HELIOS  | HELIOS | – | – | – | [53] |
| – | ZFP57 (KRAZ1) | KAP1 | DNA-binding corepressor | – | – | [54] |
| – | ZFP68 (KRAZ2) | – | – | – | – | [54] |
| – | ZFP97 (AI046551) | – | – | – | – | [33] |
| **DNA methylation** | *DMAP1* | DMAP1 | DMAP1 | DNA methyltransferase | – | – | [13] |
| *MBD-like* | MBD1, -2, -4 | MBD1 | Binds to methylated CpG, recruits SETDB1 | Autism. Prostate, lung, breast, intestine, colon, gastric cancer. | G protein–coupled receptors andreceptor tyrosine kinases(ERK/MAPK, PI3K/AKT,JAK/STAT, JNK, PKC); WNT/β-catenin. | [55] |
| – | DNMT3a, DNMT3b (MommeD14) | DNMT3B | DNA methyltransferase | Immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome. Colorectal, breast cancer. | Steroid hormones/nuclear receptors; WNT/β-catenin. | [56] |
| – | DNMT1 (MommeD2) | DNMT1 | DNA methyltransferase | Schizophrenia Late onset Alzheimer’s disease (LOAD). Prostate, breast, lung, colorectal, gastric cancer, hepatocellularcarcinoma. | Steroid hormones/nuclear receptors; WNT/β-catenin. | [13] |
| – | KAISO  | KAISO | – | – | WNT/β-catenin. | [57] |
| – | MBD3l1b | – | – | – | – | [58] |
| – | MECP2 | MECP2 | Binds to methylated CpG | Rett syndrome (cerebroatrophic hyperammonemia). |  | [59] |
| – | UHRF -1 | UHRF1 | – | – | – | [60]  |
| – | ZBTB4 | ZBTB4 | – | – | – | [57] |
| – | ZBTB38 (CIBZ) | – | – | – | – | [61] |
| **HUSH-complex** | – | – | TASOR | – | – | – | [12] |
| – | – | MPHOSPH8 | – | – | – | [12] |
| – | – | PPHLN1 | – | – | – | [12] |
| **Replication** | *Cdc6* | CDC6 | CDC6 | – | – | Steroid hormones/nuclear receptors. | [62] |
| *Orc1* | ORC1 | ORC1 | Binds to origins of replication | – | – | [63] |
| *Orc2* | ORC2l | ORC2 | ATP-dependent subunit of the origin replication complex | – | – | [62] |
| *mus209* | PCNA | PCNA | Subunit of the origin replication complex | – | – | [64] |
| *SuUR* | – | – | Heterochromatin protein, suppressor of underreplication | – | – | [65] |
| **Chromosome segregation** | *Incenp* | INCENP | INCENP | AURKB activator, centromere component  | – | – | [66] |
| **Transcription factors** | *E(var)3-93E* | E2F1 | E2F1 | E2F transcription factor, haplo-enhancer/triplo-suppressor | – | WNT/β-catenin. | [67] |
| *slbo* | C/EBPα, C/EBPβ |  |  | – | – | [68, 69] |

**Table 2**. Diseases associated with PEV of the human genes in the result of chromosome rearrangements.

 \* PEV is not confirmed.

“–” - no data.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Distance to the breakpoint** | **Diseases** | **References** |
| **Upstream** | **Downstream** |
| *SOX9* | ~900 kb. | 1,3 mb. | Campomelic dysplasia,Pierre Robin sequence \* | [70-72] |
| *POU3F4* | ~900 kb.  | – | X-linked congenital deafness | [73] |
| *FKHL7* | ~1,2 mb. | – | Anterior segment dysgenesis | [74] |
| *MAF* | ~1 mb. | – | Cataract, coloboma, anterior segment dysgenesis | [75] |
| *SHH* | ~250 kb.; ~ 1 mb. | – | Preaxial polydactyly,Holoprosencephaly \* | [76, 77] |
| *FOXL2* | ~170 kb. | – | Blepharophimosis | [78] |
| *PAX6* | – | ~150 kb. | Aniridia |  |
| *PLP1* | – | – | Spastic paraplegia type 2,Pelizaeus–Merzbacher disease | [79, 80] |
| *NSD1* | – | – | Beckwith–Wiedemann syndrome,Sotos syndrome | [81] |

**Table 3**. Human diseases developing as a result of PEV caused by microsatellite expansion (from [82] with modifications).

“–” - no data.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Repeat unit** | **Gene undergoing PEV** | **Disease** | **Inheritance pattern** | **Healthy range, no. of repeats** | **Symptomatic range, no. of repeats** | **References** |
| CCG/CGG | *XYLT1* | Baratela--Scott syndrome (BSS) | Autosomal recessive | 9-20 | 100-800 | [83, 84] |
| CCG/CGG | *DIP2B* | Mental retardation, associated with fragile site FRA12A | Autosomal dominant | 12-26 | >150 | [85] |
| CCG/CGG | *FMR1* | Fragile X mental retardation syndrome (Fragile X syndrome (FXS)) | X-linked dominant | 6-52 | >200 | [86-88] |
| CCG/CGG | *FMR2* | Mental retardation, X-linked, associated with fragile site FRAXE | X-linked recessive | 4-39 | >200 | [89-92] |
| CCG/CGG | *NOTCH2NLC* | Neuronal intranuclear inclusion disease (NIID) | Autosomal dominant | 13-30 | 60-959 | [93-96] |
| CAG | *PPP2R2B* | Spinocerebellar ataxia 12 (SCA12) | Autosomal dominant | 6-39 | 41-83 | [93-95] |
| GCA | *GLS* | Glutaminase deficiency (GD) | –  | 8-16 | >400 | [97] |

REFERENCE LIST:

1. Elgin S.C., Reuter G. 2013. Position-effect variegation, heterochromatin formation, and gene silencing in Drosophila. *Cold Spring Harb Perspect Biol*. **5**, a017780.

2. Fodor B.D., Shukeir N., Reuter G., Jenuwein T. 2010. Mammalian Su(var) genes in chromatin control. *Annu Rev Cell Dev Biol*. **26**, 471-501.

3. Catez F., Brown D.T., Misteli T., Bustin M. 2002. Competition between histone H1 and HMGN proteins for chromatin binding sites. *EMBO Rep*. **3**, 760-766.

4. Bulynko Y.A., Hsing L.C., Mason R.W., Tremethick D.J., Grigoryev S.A. 2006. Cathepsin L stabilizes the histone modification landscape on the Y chromosome and pericentromeric heterochromatin. *Mol Cell Biol*. **26**, 4172-4184.

5. Wang Y., Zhang W., Jin Y., Johansen J., Johansen K.M. 2001. The JIL-1 tandem kinase mediates histone H3 phosphorylation and is required for maintenance of chromatin structure in Drosophila. *Cell*. **105**, 433-443.

6. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., Haegeman G. 2003. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). *EMBO J*. **22**, 1313-1324.

7. Aagaard L., Laible G., Selenko P., Schmid M., Dorn R., Schotta G., Kuhfittig S., Wolf A., Lebersorger A., Singh P.B., Reuter G., Jenuwein T. 1999. Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 encode centromere-associated proteins which complex with the heterochromatin component M31. *EMBO J*. **18**, 1923-1938.

8. Schotta G., Lachner M., Sarma K., Ebert A., Sengupta R., Reuter G., Reinberg D., Jenuwein T. 2004. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. *Genes Dev*. **18**, 1251-1262.

9. Bromberg K.D., Mitchell T.R., Upadhyay A.K., Jakob C.G., Jhala M.A., Comess K.M., Lasko L.M., Li C., Tuzon C.T., Dai Y., Li F., Eram M.S., Nuber A., Soni N.B., Manaves V., Algire M.A., Sweis R.F., Torrent M., Schotta G., Sun C., Michaelides M.R., Shoemaker A.R., Arrowsmith C.H., Brown P.J., Santhakumar V., Martin A., Rice J.C., Chiang G.G., Vedadi M., Barsyte-Lovejoy D., Pappano W.N. 2017. The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. *Nat Chem Biol*. **13**, 317-324.

10. Wu H., Siarheyeva A., Zeng H., Lam R., Dong A., Wu X.H., Li Y., Schapira M., Vedadi M., Min J. 2013. Crystal structures of the human histone H4K20 methyltransferases SUV420H1 and SUV420H2. *FEBS Lett*. **587**, 3859-3868.

11. Ayyanathan K., Lechner M.S., Bell P., Maul G.G., Schultz D.C., Yamada Y., Tanaka K., Torigoe K., Rauscher F.J., 3rd 2003. Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. *Genes Dev*. **17**, 1855-1869.

12. Tchasovnikarova I.A., Timms R.T., Matheson N.J., Wals K., Antrobus R., Gottgens B., Dougan G., Dawson M.A., Lehner P.J. 2015. GENE SILENCING. Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. *Science*. **348**, 1481-1485.

13. Rountree M.R., Bachman K.E., Baylin S.B. 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. *Nat Genet*. **25**, 269-277.

14. Czermin B., Schotta G., Hulsmann B.B., Brehm A., Becker P.B., Reuter G., Imhof A. 2001. Physical and functional association of SU(VAR)3-9 and HDAC1 in Drosophila. *EMBO Rep*. **2**, 915-919.

15. Hassig C.A., Tong J.K., Fleischer T.C., Owa T., Grable P.G., Ayer D.E., Schreiber S.L. 1998. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. *Proc Natl Acad Sci U S A*. **95**, 3519-3524.

16. Di Stefano L., Ji J.Y., Moon N.S., Herr A., Dyson N. 2007. Mutation of Drosophila Lsd1 disrupts H3-K4 methylation, resulting in tissue-specific defects during development. *Curr Biol*. **17**, 808-812.

17. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A. 2004. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell*. **119**, 941-953.

18. Baksa K., Morawietz H., Dombradi V., Axton M., Taubert H., Szabo G., Torok I., Udvardy A., Gyurkovics H., Szoor B., et al. 1993. Mutations in the protein phosphatase 1 gene at 87B can differentially affect suppression of position-effect variegation and mitosis in *Drosophila melanogaster*. *Genetics*. **135**, 117-125.

19. Crosio C., Fimia G.M., Loury R., Kimura M., Okano Y., Zhou H., Sen S., Allis C.D., Sassone-Corsi P. 2002. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. *Mol Cell Biol*. **22**, 874-885.

20. Feng Y., Vlassis A., Roques C., Lalonde M.E., Gonzalez-Aguilera C., Lambert J.P., Lee S.B., Zhao X., Alabert C., Johansen J.V., Paquet E., Yang X.J., Gingras A.C., Cote J., Groth A. 2016. BRPF3-HBO1 regulates replication origin activation and histone H3K14 acetylation. *EMBO J*. **35**, 176-192.

21. Puschendorf M., Terranova R., Boutsma E., Mao X., Isono K., Brykczynska U., Kolb C., Otte A.P., Koseki H., Orkin S.H., van Lohuizen M., Peters A.H. 2008. PRC1 and Suv39h specify parental asymmetry at constitutive heterochromatin in early mouse embryos. *Nat Genet*. **40**, 411-420.

22. Horsley D., Hutchings A., Butcher G.W., Singh P.B. 1996. M32, a murine homologue of Drosophila heterochromatin protein 1 (HP1), localises to euchromatin within interphase nuclei and is largely excluded from constitutive heterochromatin. *Cytogenet Cell Genet*. **73**, 308-311.

23. Wreggett K.A., Hill F., James P.S., Hutchings A., Butcher G.W., Singh P.B. 1994. A mammalian homologue of Drosophila heterochromatin protein 1 (HP1) is a component of constitutive heterochromatin. *Cytogenet Cell Genet*. **66**, 99-103.

24. Shaffer C.D., Cenci G., Thompson B., Stephens G.E., Slawson E.E., Adu-Wusu K., Gatti M., Elgin S.C. 2006. The large isoform of Drosophila melanogaster heterochromatin protein 2 plays a critical role in gene silencing and chromosome structure. *Genetics*. **174**, 1189-1204.

25. Strodicke M., Karberg S., Korge G. 2000. Domina (Dom), a new Drosophila member of the FKH/WH gene family, affects morphogenesis and is a suppressor of position-effect variegation. *Mech Dev*. **96**, 67-78.

26. Vandamme J., Volkel P., Rosnoblet C., Le Faou P., Angrand P.O. 2011. Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. *Mol Cell Proteomics*. **10**, M110 002642.

27. Gray F., Cho H.J., Shukla S., He S., Harris A., Boytsov B., Jaremko L., Jaremko M., Demeler B., Lawlor E.R., Grembecka J., Cierpicki T. 2016. BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization. *Nat Commun*. **7**, 13343.

28. Ishov A.M., Vladimirova O.V., Maul G.G. 2004. Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX. *J Cell Sci*. **117**, 3807-3820.

29. Whitelaw N.C., Chong S., Morgan D.K., Nestor C., Bruxner T.J., Ashe A., Lambley E., Meehan R., Whitelaw E. 2010. Reduced levels of two modifiers of epigenetic gene silencing, Dnmt3a and Trim28, cause increased phenotypic noise. *Genome Biol*. **11**, R111.

30. Friedman J.R., Fredericks W.J., Jensen D.E., Speicher D.W., Huang X.P., Neilson E.G., Rauscher F.J., 3rd 1996. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. *Genes Dev*. **10**, 2067-2078.

31. Ryan R.F., Schultz D.C., Ayyanathan K., Singh P.B., Friedman J.R., Fredericks W.J., Rauscher F.J., 3rd 1999. KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a potential role for Kruppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. *Mol Cell Biol*. **19**, 4366-4378.

32. McDowell T.L., Gibbons R.J., Sutherland H., O'Rourke D.M., Bickmore W.A., Pombo A., Turley H., Gatter K., Picketts D.J., Buckle V.J., Chapman L., Rhodes D., Higgs D.R. 1999. Localization of a putative transcriptional regulator (ATRX) at pericentromeric heterochromatin and the short arms of acrocentric chromosomes. *Proc Natl Acad Sci U S A*. **96**, 13983-13988.

33. Sutherland H.G., Mumford G.K., Newton K., Ford L.V., Farrall R., Dellaire G., Caceres J.F., Bickmore W.A. 2001. Large-scale identification of mammalian proteins localized to nuclear sub-compartments. *Hum Mol Genet*. **10**, 1995-2011.

34. Bozhenok L., Wade P.A., Varga-Weisz P. 2002. WSTF-ISWI chromatin remodeling complex targets heterochromatic replication foci. *EMBO J*. **21**, 2231-2241.

35. Ohfuchi E., Kato M., Sasaki M., Sugimoto K., Oma Y., Harata M. 2006. Vertebrate Arp6, a novel nuclear actin-related protein, interacts with heterochromatin protein 1. *Eur J Cell Biol*. **85**, 411-421.

36. Buchner K., Roth P., Schotta G., Krauss V., Saumweber H., Reuter G., Dorn R. 2000. Genetic and molecular complexity of the position effect variegation modifier mod(mdg4) in Drosophila. *Genetics*. **155**, 141-157.

37. Cong L., Pakala S.B., Ohshiro K., Li D.Q., Kumar R. 2011. SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function. *J Biol Chem*. **286**, 43793-43808.

38. Ma G., Li S., Han Y., Yue T., Wang B., Jiang J. 2016. Regulation of Smoothened Trafficking and Hedgehog Signaling by the SUMO Pathway. *Dev Cell*. **39**, 438-451.

39. Muller P., Kuttenkeuler D., Gesellchen V., Zeidler M.P., Boutros M. 2005. Identification of JAK/STAT signalling components by genome-wide RNA interference. *Nature*. **436**, 871-875.

40. Henchoz S., De Rubertis F., Pauli D., Spierer P. 1996. The dose of a putative ubiquitin-specific protease affects position-effect variegation in *Drosophila melanogaster*. *Mol Cell Biol*. **16**, 5717-5725.

41. Larsson J., Zhang J., Rasmuson-Lestander A. 1996. Mutations in the *Drosophila melanogaster* gene encoding S-adenosylmethionine synthetase suppress position-effect variegation. *Genetics*. **143**, 887-896.

42. Yan Q., Huang J., Fan T., Zhu H., Muegge K. 2003. Lsh, a modulator of CpG methylation, is crucial for normal histone methylation. *EMBO J*. **22**, 5154-5162.

43. Aulner N., Monod C., Mandicourt G., Jullien D., Cuvier O., Sall A., Janssen S., Laemmli U.K., Kas E. 2002. The AT-hook protein D1 is essential for *Drosophila melanogaster* development and is implicated in position-effect variegation. *Mol Cell Biol*. **22**, 1218-1232.

44. Harrer M., Luhrs H., Bustin M., Scheer U., Hock R. 2004. Dynamic interaction of HMGA1a proteins with chromatin. *J Cell Sci*. **117**, 3459-3471.

45. Perrin L., Demakova O., Fanti L., Kallenbach S., Saingery S., Mal'ceva N.I., Pimpinelli S., Zhimulev I., Pradel J. 1998. Dynamics of the sub-nuclear distribution of Modulo and the regulation of position-effect variegation by nucleolus in Drosophila. *J Cell Sci*. **111 ( Pt 18)**, 2753-2761.

46. Gabriele M., Vulto-van Silfhout A.T., Germain P.L., Vitriolo A., Kumar R., Douglas E., Haan E., Kosaki K., Takenouchi T., Rauch A., Steindl K., Frengen E., Misceo D., Pedurupillay C.R.J., Stromme P., Rosenfeld J.A., Shao Y., Craigen W.J., Schaaf C.P., Rodriguez-Buritica D., Farach L., Friedman J., Thulin P., McLean S.D., Nugent K.M., Morton J., Nicholl J., Andrieux J., Stray-Pedersen A., Chambon P., Patrier S., Lynch S.A., Kjaergaard S., Torring P.M., Brasch-Andersen C., Ronan A., van Haeringen A., Anderson P.J., Powis Z., Brunner H.G., Pfundt R., Schuurs-Hoeijmakers J.H.M., van Bon B.W.M., Lelieveld S., Gilissen C., Nillesen W.M., Vissers L., Gecz J., Koolen D.A., Testa G., de Vries B.B.A. 2017. YY1 Haploinsufficiency Causes an Intellectual Disability Syndrome Featuring Transcriptional and Chromatin Dysfunction. *Am J Hum Genet*. **100**, 907-925.

47. Shestakova E.A., Mansuroglu Z., Mokrani H., Ghinea N., Bonnefoy E. 2004. Transcription factor YY1 associates with pericentromeric gamma-satellite DNA in cycling but not in quiescent (G0) cells. *Nucleic Acids Res*. **32**, 4390-4399.

48. Ebert A., Lein S., Schotta G., Reuter G. 2006. Histone modification and the control of heterochromatic gene silencing in Drosophila. *Chromosome Res*. **14**, 377-392.

49. Netzer C., Rieger L., Brero A., Zhang C.D., Hinzke M., Kohlhase J., Bohlander S.K. 2001. SALL1, the gene mutated in Townes-Brocks syndrome, encodes a transcriptional repressor which interacts with TRF1/PIN2 and localizes to pericentromeric heterochromatin. *Hum Mol Genet*. **10**, 3017-3024.

50. Yamashita K., Sato A., Asashima M., Wang P.C., Nishinakamura R. 2007. Mouse homolog of SALL1, a causative gene for Townes-Brocks syndrome, binds to A/T-rich sequences in pericentric heterochromatin via its C-terminal zinc finger domains. *Genes Cells*. **12**, 171-182.

51. Vassen L., Fiolka K., Moroy T. 2006. Gfi1b alters histone methylation at target gene promoters and sites of gamma-satellite containing heterochromatin. *EMBO J*. **25**, 2409-2419.

52. Benyajati C., Mueller L., Xu N., Pappano M., Gao J., Mosammaparast M., Conklin D., Granok H., Craig C., Elgin S. 1997. Multiple isoforms of GAGA factor, a critical component of chromatin structure. *Nucleic Acids Res*. **25**, 3345-3353.

53. Hahm K., Cobb B.S., McCarty A.S., Brown K.E., Klug C.A., Lee R., Akashi K., Weissman I.L., Fisher A.G., Smale S.T. 1998. Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. *Genes Dev*. **12**, 782-796.

54. Matsuda E., Agata Y., Sugai M., Katakai T., Gonda H., Shimizu A. 2001. Targeting of Kruppel-associated box-containing zinc finger proteins to centromeric heterochromatin. Implication for the gene silencing mechanisms. *J Biol Chem*. **276**, 14222-14229.

55. Hendrich B., Bird A. 1998. Identification and characterization of a family of mammalian methyl-CpG binding proteins. *Mol Cell Biol*. **18**, 6538-6547.

56. Bachman K.E., Rountree M.R., Baylin S.B. 2001. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. *J Biol Chem*. **276**, 32282-32287.

57. Filion G.J., Zhenilo S., Salozhin S., Yamada D., Prokhortchouk E., Defossez P.A. 2006. A family of human zinc finger proteins that bind methylated DNA and repress transcription. *Mol Cell Biol*. **26**, 169-181.

58. Jiang C.L., Jin S.G., Pfeifer G.P. 2004. MBD3L1 is a transcriptional repressor that interacts with methyl-CpG-binding protein 2 (MBD2) and components of the NuRD complex. *J Biol Chem*. **279**, 52456-52464.

59. Brero A., Easwaran H.P., Nowak D., Grunewald I., Cremer T., Leonhardt H., Cardoso M.C. 2005. Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation. *J Cell Biol*. **169**, 733-743.

60. Bostick M., Kim J.K., Esteve P.O., Clark A., Pradhan S., Jacobsen S.E. 2007. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. *Science*. **317**, 1760-1764.

61. Sasai N., Matsuda E., Sarashina E., Ishida Y., Kawaichi M. 2005. Identification of a novel BTB-zinc finger transcriptional repressor, CIBZ, that interacts with CtBP corepressor. *Genes Cells*. **10**, 871-885.

62. Auth T., Kunkel E., Grummt F. 2006. Interaction between HP1alpha and replication proteins in mammalian cells. *Exp Cell Res*. **312**, 3349-3359.

63. Lidonnici M.R., Rossi R., Paixao S., Mendoza-Maldonado R., Paolinelli R., Arcangeli C., Giacca M., Biamonti G., Montecucco A. 2004. Subnuclear distribution of the largest subunit of the human origin recognition complex during the cell cycle. *J Cell Sci*. **117**, 5221-5231.

64. Takasaki Y., Deng J.S., Tan E.M. 1981. A nuclear antigen associated with cell proliferation and blast transformation. *J Exp Med*. **154**, 1899-1909.

65. Belyaeva E.S., Boldyreva L.V., Volkova E.I., Nanayev R.A., Alekseyenko A.A., Zhimulev I.F. 2003. Effect of the *Suppressor of Underreplication (SuUR)* gene on position-effect variegation silencing in *Drosophila melanogaster*. *Genetics*. **165**, 1209-1220.

66. Parra M.T., Viera A., Gomez R., Page J., Carmena M., Earnshaw W.C., Rufas J.S., Suja J.A. 2003. Dynamic relocalization of the chromosomal passenger complex proteins inner centromere protein (INCENP) and aurora-B kinase during male mouse meiosis. *J Cell Sci*. **116**, 961-974.

67. Sladek T.L. 1997. E2F transcription factor action, regulation and possible role in human cancer. *Cell Prolif*. **30**, 97-105.

68. Berberich-Siebelt F., Berberich I., Andrulis M., Santner-Nanan B., Jha M.K., Klein-Hessling S., Schimpl A., Serfling E. 2006. SUMOylation interferes with CCAAT/enhancer-binding protein beta-mediated c-myc repression, but not IL-4 activation in T cells. *J Immunol*. **176**, 4843-4851.

69. Liu X., Wu B., Szary J., Kofoed E.M., Schaufele F. 2007. Functional sequestration of transcription factor activity by repetitive DNA. *J Biol Chem*. **282**, 20868-20876.

70. Pfeifer D., Kist R., Dewar K., Devon K., Lander E.S., Birren B., Korniszewski L., Back E., Scherer G. 1999. Campomelic dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9: evidence for an extended control region. *Am J Hum Genet*. **65**, 111-124.

71. Velagaleti G.V., Bien-Willner G.A., Northup J.K., Lockhart L.H., Hawkins J.C., Jalal S.M., Withers M., Lupski J.R., Stankiewicz P. 2005. Position effects due to chromosome breakpoints that map approximately 900 Kb upstream and approximately 1.3 Mb downstream of SOX9 in two patients with campomelic dysplasia. *Am J Hum Genet*. **76**, 652-662.

72. Benko S., Fantes J.A., Amiel J., Kleinjan D.J., Thomas S., Ramsay J., Jamshidi N., Essafi A., Heaney S., Gordon C.T., McBride D., Golzio C., Fisher M., Perry P., Abadie V., Ayuso C., Holder-Espinasse M., Kilpatrick N., Lees M.M., Picard A., Temple I.K., Thomas P., Vazquez M.P., Vekemans M., Roest Crollius H., Hastie N.D., Munnich A., Etchevers H.C., Pelet A., Farlie P.G., Fitzpatrick D.R., Lyonnet S. 2009. Highly conserved non-coding elements on either side of SOX9 associated with Pierre Robin sequence. *Nat Genet*. **41**, 359-364.

73. de Kok Y.J., Vossenaar E.R., Cremers C.W., Dahl N., Laporte J., Hu L.J., Lacombe D., Fischel-Ghodsian N., Friedman R.A., Parnes L.S., Thorpe P., Bitner-Glindzicz M., Pander H.J., Heilbronner H., Graveline J., den Dunnen J.T., Brunner H.G., Ropers H.H., Cremers F.P. 1996. Identification of a hot spot for microdeletions in patients with X-linked deafness type 3 (DFN3) 900 kb proximal to the DFN3 gene POU3F4. *Hum Mol Genet*. **5**, 1229-1235.

74. Davies A.F., Mirza G., Flinter F., Ragoussis J. 1999. An interstitial deletion of 6p24-p25 proximal to the FKHL7 locus and including AP-2alpha that affects anterior eye chamber development. *J Med Genet*. **36**, 708-710.

75. Jamieson R.V., Perveen R., Kerr B., Carette M., Yardley J., Heon E., Wirth M.G., van Heyningen V., Donnai D., Munier F., Black G.C. 2002. Domain disruption and mutation of the bZIP transcription factor, MAF, associated with cataract, ocular anterior segment dysgenesis and coloboma. *Hum Mol Genet*. **11**, 33-42.

76. Belloni E., Muenke M., Roessler E., Traverso G., Siegel-Bartelt J., Frumkin A., Mitchell H.F., Donis-Keller H., Helms C., Hing A.V., Heng H.H., Koop B., Martindale D., Rommens J.M., Tsui L.C., Scherer S.W. 1996. Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly. *Nat Genet*. **14**, 353-356.

77. Roessler E., Ward D.E., Gaudenz K., Belloni E., Scherer S.W., Donnai D., Siegel-Bartelt J., Tsui L.C., Muenke M. 1997. Cytogenetic rearrangements involving the loss of the Sonic Hedgehog gene at 7q36 cause holoprosencephaly. *Hum Genet*. **100**, 172-181.

78. Crisponi L., Uda M., Deiana M., Loi A., Nagaraja R., Chiappe F., Schlessinger D., Cao A., Pilia G. 2004. FOXL2 inactivation by a translocation 171 kb away: analysis of 500 kb of chromosome 3 for candidate long-range regulatory sequences. *Genomics*. **83**, 757-764.

79. Lee J.A., Madrid R.E., Sperle K., Ritterson C.M., Hobson G.M., Garbern J., Lupski J.R., Inoue K. 2006. Spastic paraplegia type 2 associated with axonal neuropathy and apparent PLP1 position effect. *Ann Neurol*. **59**, 398-403.

80. Muncke N., Wogatzky B.S., Breuning M., Sistermans E.A., Endris V., Ross M., Vetrie D., Catsman-Berrevoets C.E., Rappold G. 2004. Position effect on PLP1 may cause a subset of Pelizaeus-Merzbacher disease symptoms. *J Med Genet*. **41**, e121.

81. Shen J.J., Kurotaki N., Patel A., Lupski J.R., Brown C.W. 2005. Low factor XII level in an individual with Sotos syndrome. *Pediatr Blood Cancer*. **44**, 187-189.

82. Khristich A.N., Mirkin S.M. 2020. On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability. *J Biol Chem*. **295**, 4134-4170.

83. Faust I., Boker K.O., Lichtenberg C., Kuhn J., Knabbe C., Hendig D. 2014. First description of the complete human xylosyltransferase-I promoter region. *BMC Genet*. **15**, 129.

84. LaCroix A.J., Stabley D., Sahraoui R., Adam M.P., Mehaffey M., Kernan K., Myers C.T., Fagerstrom C., Anadiotis G., Akkari Y.M., Robbins K.M., Gripp K.W., Baratela W.A.R., Bober M.B., Duker A.L., Doherty D., Dempsey J.C., Miller D.G., Kircher M., Bamshad M.J., Nickerson D.A., Mefford H.C., Sol-Church K. 2019. GGC Repeat expansion and exon 1 methylation of XYLT1 Is a common pathogenic variant in Baratela-Scott syndrome. *Am J Hum Genet*. **104**, 35-44.

85. Winnepenninckx B., Debacker K., Ramsay J., Smeets D., Smits A., FitzPatrick D.R., Kooy R.F. 2007. CGG-repeat expansion in the DIP2B gene is associated with the fragile site FRA12A on chromosome 12q13.1. *Am J Hum Genet*. **80**, 221-231.

86. Lukusa T., Fryns J.P. 2008. Human chromosome fragility. *Biochim Biophys Acta*. **1779**, 3-16.

87. Kremer E.J., Pritchard M., Lynch M., Yu S., Holman K., Baker E., Warren S.T., Schlessinger D., Sutherland G.R., Richards R.I. 1991. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. *Science*. **252**, 1711-1714.

88. Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.H., Kuhl D.P., Pizzuti A., Reiner O., Richards S., Victoria M.F., Zhang F.P., et al. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell*. **65**, 905-914.

89. Knight S.J., Flannery A.V., Hirst M.C., Campbell L., Christodoulou Z., Phelps S.R., Pointon J., Middleton-Price H.R., Barnicoat A., Pembrey M.E., et al. 1993. Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. *Cell*. **74**, 127-134.

90. Gecz J., Gedeon A.K., Sutherland G.R., Mulley J.C. 1996. Identification of the gene FMR2, associated with FRAXE mental retardation. *Nat Genet*. **13**, 105-108.

91. Gu Y., Shen Y., Gibbs R.A., Nelson D.L. 1996. Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island. *Nat Genet*. **13**, 109-113.

92. Bensaid M., Melko M., Bechara E.G., Davidovic L., Berretta A., Catania M.V., Gecz J., Lalli E., Bardoni B. 2009. FRAXE-associated mental retardation protein (FMR2) is an RNA-binding protein with high affinity for G-quartet RNA forming structure. *Nucleic Acids Res*. **37**, 1269-1279.

93. Lu X., Hong D. 2021. Neuronal intranuclear inclusion disease: recognition and update. *J Neural Transm (Vienna)*. **128**, 295-303.

94. Tian Y., Wang J.L., Huang W., Zeng S., Jiao B., Liu Z., Chen Z., Li Y., Wang Y., Min H.X., Wang X.J., You Y., Zhang R.X., Chen X.Y., Yi F., Zhou Y.F., Long H.Y., Zhou C.J., Hou X., Wang J.P., Xie B., Liang F., Yang Z.Y., Sun Q.Y., Allen E.G., Shafik A.M., Kong H.E., Guo J.F., Yan X.X., Hu Z.M., Xia K., Jiang H., Xu H.W., Duan R.H., Jin P., Tang B.S., Shen L. 2019. Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders. *Am J Hum Genet*. **105**, 166-176.

95. Sone J., Mitsuhashi S., Fujita A., Mizuguchi T., Hamanaka K., Mori K., Koike H., Hashiguchi A., Takashima H., Sugiyama H., Kohno Y., Takiyama Y., Maeda K., Doi H., Koyano S., Takeuchi H., Kawamoto M., Kohara N., Ando T., Ieda T., Kita Y., Kokubun N., Tsuboi Y., Katoh K., Kino Y., Katsuno M., Iwasaki Y., Yoshida M., Tanaka F., Suzuki I.K., Frith M.C., Matsumoto N., Sobue G. 2019. Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. *Nat Genet*. **51**, 1215-1221.

96. Sun Q.Y., Xu Q., Tian Y., Hu Z.M., Qin L.X., Yang J.X., Huang W., Xue J., Li J.C., Zeng S., Wang Y., Min H.X., Chen X.Y., Wang J.P., Xie B., Liang F., Zhang H.N., Wang C.Y., Lei L.F., Yan X.X., Xu H.W., Duan R.H., Xia K., Liu J.Y., Jiang H., Shen L., Guo J.F., Tang B.S. 2020. Expansion of GGC repeat in the human-specific NOTCH2NLC gene is associated with essential tremor. *Brain*. **143**, 222-233.

97. van Kuilenburg A.B.P., Usdin K., van Karnebeek C.D.M. 2019. Glutaminase deficiency caused by short tandem repeat expansion in GLS. Reply. *N Engl J Med*. **381**, 1185.